Guardian Pharmacy Services vs PetMed Express
GRDN and PETS side by side, both in miscellaneous retail. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRDN and PETS compare
Guardian Pharmacy Services is the larger company, worth 137 times as much as PetMed Express ($3.2B against $23.1M).
Guardian Pharmacy Services grew revenue faster over the last twelve months (4.9% versus −19.2% for PetMed Express).
Guardian Pharmacy Services keeps more of each dollar of sales as profit, with a net margin of 5.1% compared with −17.0% at PetMed Express.
Guardian Pharmacy Services scores higher on the StockData Score (9 against 7 for PetMed Express), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRDN | PETS |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $23.1M |
| Share price | $49.98 | $1.06 |
| Change, 1 year | 68.0% | −59.2% |
| Change, 5 years | – | −96.4% |
| Beta (5Y) | 0.56 | 0.85 |
| Employees | 3,600 | 189 |
| StockData Score | ||
| Total score | 9 (better) | 7 |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.2× | 0.1× (better) |
| P/B | – | 1.4× |
| EV/EBITDA | 26.0× | – |
| FCF yield | – | −107% |
| Fair value | $19.44 | $2.55 |
| Margin of safety | −157% | 58.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 4.9% (better) | −19.2% |
| Revenue growth, 5Y average | – | −10.0% |
| Net income growth (TTM) | 85.8% | – |
| Profitability | ||
| Gross margin | 22.4% | 27.8% (better) |
| Operating margin | 6.5% (better) | −18.0% |
| Net margin | 5.1% (better) | −17.0% |
| FCF margin | – | −15.4% |
| Return on equity | – | −90.8% |
| Return on invested capital | – | −367% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | 145× | – |
| Current ratio | 1.65 (better) | 0.60 |
| Altman Z-score | 13.18 (better) | 1.00 |
| Piotroski F-score | 7 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | −0.96% | – |
| Shareholder yield | −0.96% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 46.6% | 21.4% |
| Held by insiders | 43.6% | 32.7% |
| Insider net buying, 12 months | −$419M | $43.8K (better) |
| Short interest, % of float | 6.2% | 5.7% |
Go deeper
- GRDN stock overview
- GRDN income statement
- GRDN valuation and score
- PETS stock overview
- PETS income statement
- PETS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.